Investors expect earnings season to be about growth. This quarter, big pharma’s focus on cost-cutting and M&A revealed how deep the organic growth problem runs. Meanwhile, one merger rumor exposed the fragility beneath AstraZeneca’s bullish targets.
Investors expect earnings season to be about growth. This quarter, big pharma’s focus on cost-cutting and M&A revealed how deep the organic growth problem runs. Meanwhile, one merger rumor exposed the fragility beneath AstraZeneca’s bullish targets.